Regeneron’s Cemiplimab-rwlc (LIBTAYO) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who candidates for curative surgery or...